07 Oct 2026, 15:25 IST
Aurobindo Pharma Limited
HDFC Securities · ADD · target Rs 1,730
The report expects 18% YoY revenue growth driven by Lannett integration and Europe momentum, calling it among the strong performers this quarter.
From Pharma and Healthcare Q2FY27 Preview HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.